Skip to content

The Effect of Cinnamon on HbA1c Among Adolescents With Type I Diabetes

The Effect of Cinnamon on HbA1c Among Adolescents With Type I Diabetes

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00371800
Enrollment
72
Registered
2006-09-04
Start date
2005-10-31
Completion date
2006-05-31
Last updated
2006-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes Mellitus

Keywords

Cinnamon, Type 1 Diabetes, Adolescent, HbA1c

Brief summary

the purpose of this study is to determine if cinnamon improves glucose control among adolescents with type 1 diabetes mellitus.

Detailed description

Widespread achievement of glucose control remains an elusive goal for adolescents with Type 1 diabetes. Previous research has suggested that cinnamon may be effective at improving glucose control in type 2 diabetes. To date, no research has investigated the effect of cinnamon on type 1 diabetics. If the addition of a simple, natural, pill to a standard insulin regimen can significantly improve glucose control, the clinical implications would be substantial. Comparison: Using a prospective, double-blind, placebo-controlled design, 72 adolescent type I diabetics were treated with cinnamon (1 gram/day) or an equivalent appearing placebo for 90 days. HbA1c, total daily insulin intake, and adverse events were recorded and compared between groups.

Interventions

Sponsors

Dartmouth College
CollaboratorOTHER
Dartmouth-Hitchcock Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
13 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

1. Diagnosis of Type 1 diabetes for \> 18 months prior to enrollment, 2. Age 13-18 years at the time of enrollment 3. Presenting to the clinic for routine care, 4. No hospital admissions for medical or psychiatric reasons in the 12 months prior to enrollment, 5. Accessible by phone, 6. Not pregnant.

Exclusion criteria

(1) Pregnant

Design outcomes

Primary

MeasureTime frame
HbA1c

Secondary

MeasureTime frame
Total Daily Insulin
Carbohydrate/insulin dose
Hypoglycemic events
Compliance

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026